Filtered By:
Cancer: Gastric (Stomach) Cancer
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 294 results found since Jan 2013.
Total, red and processed meat consumption and human health: an umbrella review of observational studies
Int J Food Sci Nutr. 2022 Mar 15:1-12. doi: 10.1080/09637486.2022.2050996. Online ahead of print.ABSTRACTMeat consumption has represented an important evolutionary step for humans. However, modern patterns of consumption, including excess intake, type of meat and cooking method have been the focus of attention as a potential cause of rise in non-communicable diseases. The aim of this study was to investigate the association between total, red and processed meat with health outcomes and to assess the level of evidence by performing a systematic search of meta-analyses of prospective cohort studies. Convincing evidence of th...
Source: International Journal of Food Sciences and Nutrition - March 16, 2022 Category: Nutrition Authors: Giuseppe Grosso Sandro La Vignera Rosita A Condorelli Justyna Godos Stefano Marventano Maria Tieri Francesca Ghelfi Lucilla Titta Alessandra Lafranconi Angelo Gambera Elena Alonzo Salvatore Sciacca Silvio Buscemi Sumantra Ray Daniele Del Rio Fabio Galvano Source Type: research
South Africa: North West Health On World Salt Awareness Week
[Govt of SA] The North West Department of Health urge communities to take actions during the World Salt Awareness Week which is marked on 14 - 20 March. The awareness is to educate members of the public that salt can damage their health and it is linked to serious health conditions such as stroke and heart failure. There is also increasing evidence supporting links between our current high salt diets and the onset of stomach cancer, osteoporosis, obesity and kidney stones and kidney disease.
Source: AllAfrica News: Health and Medicine - March 15, 2022 Category: African Health Source Type: news
Anticoagulation for atrial fibrillation in active cancer
Oncol Lett. 2022 Apr;23(4):124. doi: 10.3892/ol.2022.13244. Epub 2022 Feb 17.ABSTRACTAtrial fibrillation (AF) may often pre-exist in patients with newly diagnosed cancer or occur with increased frequency shortly after cancer diagnosis. Patients with active cancer and AF have a particularly high risk of thromboembolic complications, as both conditions carry a risk of thrombosis. Thromboembolic risk is determined by several factors, including advanced age, sex (females), cancer histology (adenocarcinomas), location (e.g., pancreas, stomach), advanced stage, anticancer regimens (e.g., platinum compounds, anti-angiogenic thera...
Source: Oncology Letters - March 9, 2022 Category: Cancer & Oncology Authors: Dimitrios Farmakis Pavlos Papakotoulas Eleni Angelopoulou Theodoros Bischiniotis George Giannakoulas Panagiotis Kliridis Dimitrios Richter Ioannis Paraskevaidis Source Type: research
Physical inactivity and non-communicable disease burden in low-income, middle-income and high-income countries
Conclusion
The global burden associated with physical inactivity is substantial. The relative burden is greatest in high-income countries; however, the greatest number of people (absolute burden) affected by physical inactivity are living in middle-income countries given the size of their populations.
Source: British Journal of Sports Medicine - January 3, 2022 Category: Sports Medicine Authors: Katzmarzyk, P. T., Friedenreich, C., Shiroma, E. J., Lee, I.-M. Tags: Editor's choice, Press releases, BJSM Original research Source Type: research
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
